​Our Leadership Team

​Our leadership team is composed of biotech industry veterans with many years of experience in all areas of pharmaceutical drug development, management and financing.

Dr. Peter Milner

Dr. Peter Milner is a co-founder, member of the board of managers and CEO of Renexxion. He is also Executive Chairman and co-founder of Armetheon, Inc. He was CEO of Heart Metabolics Limited UK (now HMBL) from 2011 to 2015, and of Heart Metabolics Limited Ireland from 2014 to 2015. He co-founded Optivia Biotechnology, ARYx Therapeutics, and CV Therapeutics. He serves on the board of various biotech companies.

Prior to 1992, Peter was an assistant professor of medicine at Washington University in St. Louis. He was educated at the University of Liverpool, receiving his medical degree in 1980, before completing his postgraduate training at Johns Hopkins Hospital, The University of Virginia, and Washington University in St. Louis.

He is a Fellow of the American College of Cardiology (FACC), and a board-certified physician and cardiologist. He serves as adjunct clinical faculty at Stanford University School of Medicine and as a board member of the California Healthcare Institute (CHI).

Dr. M. (Ken) Kengatharan

Dr. M. (Ken) Kengatharan is a co-founder, member of the board of managers and Chairman of Renexxion. He is also President and Co-CEO, director, and co-founder of Armetheon, Inc. He is the former President & CSO and co-founder of Altheos, Inc., and co-founder and former Vice President, Pre-Clinical R&D of Athenagen, Inc. (re-named CoMentis, Inc), all three biopharmaceutical companies are based in the San Francisco bay area.

Dr. Kengatharan obtained his PhD in pharmacology from the University of London at the William Harvey Research Institute and obtained his MBA (with Distinction) from Durham University in England, where he focused on Biotech Finance and Entrepreneurship.

Dr. Pascal Druzgala

Dr. Pascal Druzgala is a co-founder, member of the board of managers and CSO of Renexxion. He is also Senior VP and CSO, and co-founder of Armetheon. Pascal is also a co-founder and board member of Optivia Biotechnology, and a co-founder of ARYx Therapeutics (NASDAQ:ARYX), where he served as senior VP and CSO from 1997 to 2011, as well as chairman of the scientific advisory board.​Dr. Druzgala received a Pharm.D. degree from the University of Montpellier, France, and then went on to earn a diplôme d’études approfondies degree (DEA) at the European Institute of Industrial Pharmaceutical Sciences (IPIM), also in Montpellier, France. Dr. Druzgala later graduated in 1985 from the University of Florida with a doctorate in medicinal chemistry. He completed his post-doctorate work at the Center for Drug Design and Discovery at the University of Florida, where he first experimented with various drug discovery programs utilizing retrometabolic techniques. These techniques, pioneered by Dr. Nicholas Bodor in the late 1970s, are the basis for the research into enhanced safety for Armetheon’s clinical-stage drug candidate: tecarfarin and budiodarone and Renexxion’s clinical stage drug candidate: naronapride.